ライフサイエンスコーパス: cell marker

1 thelial cells that coexpressed UEA1 (surface cell marker).

2 9 and CD138 immune cells (plasmablast/plasma cell markers).

3 19 as a segment-committed nephron progenitor cell marker.

4 as might be expected for a tumor-initiating cell marker.

5 ositive for CD45, considered a hematopoietic cell marker.

6 ntified keratin 23 (KRT23) as a new ductular cell marker.

7 of p63, an important corneal epithelial stem cell marker.

8 ary acidic acid (GFAP)-expressing supporting cell marker.

9 considered a specific crypt epithelial stem cell marker.

10 were positive for Villin, a proximal tubular cell marker.

11 essing select dendritic cell, NK cell, and B cell markers.

12 ung mesenchyme and cells expressing alveolar-cell markers.

13 a corresponding decrease in established stem cell markers.

14 ral crest-derived cells that express Schwann cell markers.

15 ession of the master EMT regulators and stem cell markers.

16 activates tissue-specific expression of stem cell markers.

17 on and were negative for regulatory CD8(+) T cell markers.

18 rray of novel genes as putative corneal stem cell markers.

19 expressing homologs of known mammalian stem cell markers.

20 n of key epithelial, stromal and endothelial cell markers.

21 yte markers, oval cell markers, and stellate cell markers.

22 , and, at the single-cell level, cancer stem cell markers.

23 cell profiling of any tissues that lack live-cell markers.

24 (ii) activated RICTOR; and (iii) progenitor cell markers.

25 These tumor-initiating cells express stem cell markers.

26 reduced the expression levels of neural stem cell markers.

27 es cell proliferation and expression of stem cell markers.

28 ndothelial, podocyte, or parietal epithelial cell markers.

29 nd maintained expression of mesenchymal stem cell markers.

30 d fewer cells expressing mammary cancer stem cell markers.

31 This group included 34 NK cell markers.

32 els of Wnt activity also express cancer stem cell markers.

33 -1, one of the most commonly used adult stem cell markers.

34 tor-differentiation states or glial and stem cell markers.

35 ive real-time PCR for the expression of stem cell markers.

36 ns but lack expression of classical memory B cell markers.

37 rs and higher levels of putative limbal stem cell markers.

38 th lineages expressing Lgr5, one of the stem cell markers.

39 ent and a high expression of stem/progenitor cell markers.

40 , out of 15 studies that evaluated microglia cells markers, 8 studies found no effect of BD on these

41 f EZC progeny that continued to express stem cell markers after SCI, increased the proportion of EZC

42 s resulted in a significant decrease in stem cell markers, Aldefluor expression, proliferation, and i

43 or metastasis and the expression of the stem cell marker ALDH1A1.

44 s required for expression of the cancer stem cell marker ALDH1A3 and Wnt signalling activity.

45 -expressing cells colocalized with mesangial cell markers alpha8-integrin and PDGF receptor-beta but

46 rsistence of T cells targeting CD19, a pan-B cell marker, also depletes normal B cells and causes sev

47 atic activity has been used as a cancer stem cell marker and seems to correlate with tumour aggressiv

48 correlates with Notch and other cancer stem cell markers and can be targeted by a novel, clinically

49 ed activities, including expression of stalk-cell markers and cell proliferation, consistent with an

50 e infiltration and expression of cytotoxic T-cell markers and effector cytokines, similar in extent t

51 e identified using immunohistochemical Golgi cell markers and electron microscopic profiles of granul

52 hAFSCs co-localized with neural cell markers and expressed BDNF, TGF-beta1, GFAP, and IL

53 ed from osteoarthritic patients express stem cell markers and have chondrogenic, osteogenic, and adip

54 ent show increased expression of mature beta cell markers and improved glucose stimulated insulin sec

55 on promotes expression of hair follicle stem cell markers and induces elements of the core hair morph

56 n CD4 T cells expressing T follicular helper cell markers and inhibitory co-receptors.

57 irculated as aggregates, expressing multiple cell markers and largely externalized phosphatidylserine

58 ifferential activation of hepatic progenitor cell markers and metabolic pathways: high-risk tumors we

59 ancer that were even more enriched with stem cell markers and more tumorigenic than the freshly isola

60 eveloped a mathematical model using T- and B-cell markers and mycophenolate mofetil (MMF) dosage.

61 mation and for the expression of neural stem cell markers and Notch target genes in primary neural pr

62 asured the gene expression of various immune cell markers and performed multivariate analysis of the

63 of the maintenance and/or activation of germ cell markers and pluripotency genes.

64 mesenchymal stem cell and hepatic progenitor cell markers and produce growth factor and cytokine mRNA

65 The cells also expressed known mesenchymal cell markers and promoted new bone formation to heal cri

66 he SASP exhibit increased expression of stem cell markers and regenerative capacity in vivo.

67 hese highly proliferative cells express stem cell markers and retain the ability to differentiate dow

68 ABCG2 can actively drive expression of stem cell markers and self-renewal in glioma cells.

69 Stem cell markers and self-renewal was enriched in cells with

70 We observed high expression of epithelial cell markers and similarity to the transcriptome for int

71 rcoma cells decreases the expression of stem cell markers and suppresses sarcosphere formation, as we

72 st that expression of several canonical Treg cell markers and suppressive function could be Foxp3 ind

73 tion of cell surface and intracellular CD8 T cell markers and to compare frequencies of these cells b

74 ochemistry and immunofluorescence for immune cell markers and tumor architecture.

75 ly, chondroprogenitors begin to express stem cell markers and undergo symmetric cell division.

76 pair signaling and expression of cancer stem cells markers and sensitized chemoresistant OC cells to

77 in the expression of Sox2, a GBM cancer stem cell marker, and was obligatory for tumor formation.

78 ls in vivo, lack of crypt base columnar stem cell markers, and a failure of in vitro crypt organoid g

79 atant IL-4, serum IL-2 and IL-6, endothelial cell markers, and anti-ADAMTS13 antibody compared with c

80 ease in double negative B cells, change in B-cell markers, and elevation of unmutated IgG(+) B cells

81 symmetric division, express mesenchymal stem cell markers, and generate chondrocytes via both asymmet

82 motherapy, reduced expression of Cancer-Stem-Cell markers, and increased chemosensitivity.

83 motherapy, reduced expression of cancer stem cell markers, and increased chemosensitivity.

84 integrated into the TM tissue, expressed TM cell markers, and maintained normal IOP, outflow facilit

85 arose in germinal centers, acquired memory B cell markers, and persisted indefinitely.

86 NA damage response, pro-survival genes, stem cell markers, and self-renewal ability for survival and

87 y low expression of hepatocyte markers, oval cell markers, and stellate cell markers.

88 handling, increased mRNA expression of stem cell markers, and striking induction of many genes assoc

89 The cells expressing five of stem/progenitor cell markers are localized in basal layer of entire muri

90 We identified ALDH1A1, a cancer stem cell marker as being overexpressed in OC spheroids and d

91 dentification of Lgr5 as the intestinal stem cell marker as well as the growth factors necessary to r

92 ing alpha-cells maintain expression of alpha-cell markers, as seen by deep transcriptomic and proteom

93 e expression of mesoderm and primordial germ cell markers asymmetrically on the embryonic and extraem

94 ker expression and downregulated mesenchymal cell markers at RNA and protein level in BEAS-2B cells a

95 Insulin(low) islets also contained beta-cell markers at variable levels, including Pdx1, Nkx6.1,

96 X with OLFM4 and LGR5, two bona fide GI stem cell markers, at the crypt cells.

97 they expressed neuronal and retinal ganglion cell markers (ATOH7, POU4F2, beta-III tubulin, MAP2, TAU

98 Thy1 (also called CD90), a widely used stem cell marker, blocks adipogenesis and reduces lipid accum

99 RPMI, DMEM both expressed the putative stem cell marker Bmi-1 and yielded cell colonies.

100 localized with a type IV cell and epithelial cell marker but not type I, II, or III markers.

101 further led to increased expression of beta-cell markers but in the meantime, strongly downregulated

102 4 (OLFM4) has emerged as an intestinal stem-cell marker, but its biological function in the intestin

103 , which produced progeny that expressed hair cell markers, but proliferative responses declined postn

104 lyzed for the expression of immunomodulatory cell markers by real-time quantitative reverse transcrip

105 suppressed the expression of the cancer stem cell markers c-Myc, CD133, and nestin, which could contr

106 akers (BrdU, cyclin D1, p53) and cancer stem cell markers (CD133 and nanog) are significantly up-regu

107 tion had a reduced expression of cancer stem cell markers (CD133, CD90, CD49f) and a diminished colon

108 also reduced expression of the colonic stem cell markers, CD133 and CD44, and inhibited tumor sphere

109 ed by HSCs augmented B-cell survival, plasma cell marker CD138 expression, and immunoglobulin G produ

110 mono express higher levels of the dendritic cell marker CD1c.

111 and immunohistochemistry and expressed the T-cell markers CD2, CD3, CD4, and terminal deoxynucleotidy

112 antibody specifically targeting the human B cell marker CD20, for its ability to image B cells in a

113 ed with type 2 immune response and dendritic cell markers (CD209 and CD207).

114 upernatants enhanced the expression of the B cell markers CD23 and CD40, which are important for B ce

115 aining factors (c-Myc, Nanog and Oct4), stem cell markers (CD24 and CD133), components of Shh pathway

116 lly, cell surface expression of the CML stem cell markers CD25, CD26, and IL1RAP is high in all subpo

117 relevant genes, as for instance the memory-B cell marker CD27 and PTPRC genes, providing us with biol

118 at had a high percentage of mesenchymal stem cell markers CD29, CD44, CD146 and Stro1 and had the abi

119 increases in levels of dendritic cell and T-cell markers (CD3, ITGAX/CD11c, and CD83), but AD tissue

120 cigarette exposure increased the endothelial cell marker CD31 and CD34 to approximately 2 fold (p < 0

121 automated procedure based on the endothelial cell marker CD31 to highlight tumor vasculature.

122 e exhibit increased expression of Osm, the T cell markers Cd4 and Cd8, and the macrophage markers F4/

123 ifying neuropilin-1 (NRP1); and the helper T cell marker, CD4.

124 Notably, overexpression of the cancer stem cell marker CD44 enhanced the stability of SLC7A11 by pr

125 tionally activates expression of cancer stem cell marker CD44 in PC cells.

126 egulates alternative splicing of cancer stem cell marker CD44 through a phosphorylated T179 of SMAD3-

127 e cells gain expression of de-differentiated cell markers CD44 and cytokeratin 5 (CK5), lose luminal

128 acterized by elevated surface levels of stem cell markers CD44 and Sca1 and by rapid metastasis.

129 requency of cells expressing the cancer stem cell markers CD44, CD133, and c-Met and the immunologic

130 ronectin, vimentin, slug and snail) and stem cell markers (CD44 and CD87) in both BEAS-2B and A549 ce

131 e characteristics of CSCs by expressing stem cell markers (CD44, CD133, LGR5 and DCLK1) and transcrip

132 a and progesterone receptors, expressed stem cell marker, CD44, and displayed increased clonogenicity

133 s demonstrated CTCs positive for cancer stem cell marker, CD44, suggesting that the major population

134 Allelic variants of the pan-haematopoietic cell marker CD45, identified as CD45.1 and CD45.2, have

135 -treated humanized mice that express both NK cell marker CD56 and myeloid markers such as CD36 and CD

136 to display low-nanomolar affinity for the T-cell marker CD8) enable the traceless isolation of pure

137 immunolabeling experiments by using various cell markers combined with synaptic markers.

138 that AML cells express lymphatic endothelial cell markers consistent with lymphatic endothelial cell

139 021 reduced the growth rate, stem/progenitor cell marker content and clonogenic capacity in the expla

140 shi1 (MSI1) has been characterized as a stem cell marker, controlling the balance between self-renewa

141 terleukin (IL)-4 and, unexpectedly, the mast cell marker CPA3 predicted UCP1 gene expression.

142 oplastic lesions positive for the progenitor cell marker, cytokeratin-19 (Krt-19) and characterized b

143 robe set contained genes for specific immune cell markers, cytokines, and chemokines) on the SC WAT f

144 by a live-cell sorting method using the germ cell marker DDX4, which has previously been assumed to b

145 mRNA expression of Th1/Th2/Th17-associated cell markers decreased between 4.5 and 6 years (P < 0.00

146 ount (CBC) and inflammation-associated blood cell markers derived from them have been reported to cor

147 Although most NK-cell markers did not differ, activating receptors such a

148 e cell cycle and the expression of endocrine cell markers during differentiation, we investigated the

149 ) is earmarked by a reduction of endothelial cell markers (e.g. CD31) as well as mRNA expression of a

150 stem cell (Sca-1, CD133, Dlk) and liver stem cell markers (EpCAM, CD14, CD24, CD49f); and negative fo

151 alpha(v)beta(5) as a functional cancer stem cell marker essential for GBM maintenance and ZIKV infec

152 milar phenotypic profile of mesenchymal stem cell markers, except a relatively higher level of CD146

153 ression across cells, (3) the variability of cell marker expression across samples that (4) may vary

154 cs include increased self-renewal, high stem cell marker expression and high tumorigenic capacity in

155 tion of Akt-EphA2 cross-talk attenuated stem cell marker expression and neurosphere formation while h

156 e observed a substantial reduction of Paneth cell marker expression, although the expressions of ente

157 CD8(-) T cells, regulatory T cells, CD4(+) T cell marker expression, lifespan, and Th/regulatory T ce

158 on, and flow cytometry to assess airway stem cell marker expression.

159 ific patterns of cell proliferation and stem cell marker expression.

160 el of gene expression and its quantified IHC cell marker for CD45(+), CD3(+), CD8(+), CD4(+), and CD2

161 In addition, we validate cell markers for all these clusters by in situ hybridisa

162 Expression of the regulatory T cell markers FOXP3 and CD25, together with the immunosup

163 y individuals did not coexpress regulatory T cell markers (Foxp3(+) CD25(+)) and cultured T cell clon

164 ed immunohistochemistry to stain for B and T cell markers from formalin-fixed parffin-embedded tissue

165 Assessment of cells bearing regulatory T cell markers from these mice revealed defective function

166 eading frame downstream of the melanoma stem cell marker gene ABCB5.

167 s transition of these cells to a unique stem cell marker gene-positive, extracellular matrix-remodeli

168 del built with eight of these quiescent stem cell marker genes (GSE70696_QNPbyTAP) was sufficient to

169 nificant enrichment of rodent quiescent stem cell marker genes (GSE70696_QNPbyTAP).

170 itical tools, including highly specific stem cell marker genes along with more rigorous experimental

171 s co-expressed with multiple stem/progenitor cell marker genes in prostate epithelial cells and acts

172 rgely driven by identification of novel stem cell marker genes, revealing the existence of quiescent,

173 Using a panel of spermatogonial cell marker genes, we demonstrate that Sox3 is expressed

174 e characterized by diagnostic quiescent stem cell marker genes, which may potentially be used clinica

175 We focused on the reactive cell marker glial fibrillary acidic protein (GFAP) to st

176 ortin-3, or appeared to co-express the alpha-cell marker, glucagon.

177 xpress several pluripotent and myogenic stem cell markers; have the capability to form embryoid bodie

178 patterns of EpCAM, a hepatic stem/progenitor cell marker highly expressed in a subset of HCC with ste

179 ysis, we found higher expression of the stem cell markers HOXA9 and NANOG, as well as BMP8B, CCR6 and

180 inase C delta (PKCdelta), a CeL microcircuit cell marker implicated in rodent threat processing.

181 es in synaptic protein levels and astroglial cell marker in a region specific manner.

182 HOPX is a stem cell marker in hair follicles and intestines.

183 may be used to represent a single IHC immune cell marker in melanoma.

184 r6, but not Lgr5, acts as an epithelial stem cell marker in SCCs in vivo.

185 ies have suggested that PHLDA1 may be a stem cell marker in the human intestine that contributes to t

186 LGR5 is known to be a stem cell marker in the murine small intestine and colon, how

187 the expression of p63, a known basal/reserve cell marker in this tissue.

188 highly positive staining for epithelial stem cell markers in all areas of normal TM tissue.

189 DO1 are positively correlated with secretory cell markers in ilea of healthy individuals and Crohn's

190 Staining for other cell markers in rats treated with GLP-1(1-37)-secreting

191 activated Wnt signalling, and distinct stem-cell markers in senescence.

192 -driven target genes and alveolar epithelial cell markers in the elastase, as well as in CS-induced m

193 hology and the presence of transcripts for T cell markers in the sorted CD4-1(+)CD3epsilon(+) cells w

194 , and overlap between fibroblast and myeloid cell markers in tissues.

195 of ANGPTL4 and PDK4 paralleled that of stem cells markers in human HCC specimens.

196 ress CD133 mRNA and protein, a putative stem cell marker, in allograft biopsy samples with ACR compar

197 ivity and higher expression of CD105, a stem cell marker, in hMSCs in random versus regular patterns

198 New hair cells expressed multiple hair cell markers included Myosin VIIa, Pou4f3 and Myosin VI.

199 here formation and expression of cancer stem cell markers, including BMI1.

200 city of BTIC and decreased numerous GBM stem cell markers, including CD133, CD90, CD49f and A2B5.

201 el of NSPC and lineage-restricted progenitor cell markers, including MSI-1, SOX9, and TUJ1.

202 and failure to sustain expression of repair cell markers, including Shh, GDNF, and BDNF.

203 The abnormal epithelium expressed basal cell markers, including tumor protein 63, cytokeratin 5

204 r neuropilin-1 (NRP-1) attenuate cancer stem cell markers, inhibit the tumor-initiating cell's neuros

205 lecortin-like kinase 1 (DCLK1), a tumor stem cell marker, is induced during cirrhosis and HCC.

206 oupled receptor 5 (LGR5), an intestinal stem cell marker, is known to exhibit tumor suppressor activi

207 s) expressing the biliary/hepatic progenitor cell marker keratin 19 (K19) have been linked with a poo

208 ssion drove ectopic expression of the Merkel cell marker keratin 8 (K8) throughout the epidermis.

209 cadherin and the undifferentiated epithelial cell markers keratin 5 and 14 but not the differentiatio

210 These phmSG cells exhibited progenitor cell markers (keratin 5 and nanog) as well as acinar-spe

211 er, they did not colocalize with the Schwann cell marker Krox20, spiral ganglion marker NF200, nor gl

212 0.0 hepatoblasts that express the adult stem cell marker Lgr5, and generate both hepatocyte and chola

213 characterized by high expression of the stem cell marker Lgr5, by the expression of liver progenitor

214 ds, and messenger RNA levels of Lgr5(+) stem cell markers (Lgr5, Olfm4, Smoc2, Msi1, and Ascl2) were

215 vel EE gene expression but co-expressed tuft cell markers, Lgr5 and Ascl2, reminiscent of label-retai

216 Here we report that the lung stem cell marker Lgr6 becomes enriched in non-small cell lung

217 cell patches expressing the undifferentiated cell marker LHX9, and a loss of differentiated cells in

218 CD3, CD19, CD4, CD8 and Foxp3) and dendritic cell markers (Lineage negative [CD3, CD14, CD16, CD19, C

219 Despite its use as an NK cell marker, little is known about the role of alpha2bet

220 vestigate whether activation of EMT and stem cell markers might be involved in epigenetic regulation

221 s showed upregulation of T follicular helper cell markers, most notably CXCR5 and its ligand CXCL13,

222 arkers, but reduced expression of the goblet cell marker Mucin2 and fewer Paneth cells.

223 al of hDPSCs and other stem cells, selective cell markers must be identified in the progenitor cells.

224 ation largely negative for the skeletal stem cell markers Nestin-GFP, Leptin receptor and Gremlin1.

225 , a positive correlation between CCL5 and NK cell marker NKp46 expression was found in melanoma patie

226 low amount of IgHC sufficed to initiate PreB cell markers normally associated with PreBCR signaling.

227 tivation of expression of the embryonic stem cell markers OCT4, NANOG, SOX2 and SSEA1 and lacked expr

228 fferentiation marker and downstream effector cell marker) of IL-9 upregulation only in African Americ

229 which also had increased expression of stem cell markers (OLFM4, BMI1, and MSI1) compared with colon

230 AFSC derived EVs presented exosomal and stem cell markers on their surface membrane, including VEGFR1

231 Runx2 and Col1a1, which are early osteogenic cell markers, on day 10 after the subperiosteal injectio

232 tify genes representing common putative stem cell markers or determinants, which included Sox9, Fzd7,

233 hen become HCC cells that express progenitor cell markers), or to transdifferentiate into biliary-lik

234 However, IWP2 increased stem/progenitor cell marker (p63alpha and ABCG2) content and clonogenic

235 rrant expression of cadherins and the pillar cell markers P75 and Lgr6.

236 predominantly express the venous endothelial cell marker PAL-E, whereas CD144(+)PAL-E(-) vessels comp

237 ate the underlying distribution of the tumor cell marker pan-cytokeratin (panCK).

238 sharply elevated the expression of the beta cell markers pancreatic and duodenal homeobox 1 (Pdx1) a

239 factors, while down-regulating the satellite cell marker Pax7.

240 2 silencing inhibited the expression of stem cell markers, pluripotency maintaining transcription fac

241 Early PVR vitreous showed upregulation of T-cell markers, profibrotic cytokines, and cytokines downs

242 found that during ee cell formation, the ee cell marker Prospero localizes to the basal side of divi

243 lar epithelial cells with TNFR2-induced stem cell markers rather than expansion of resident stem cell

244 Double labeling with the ganglion cell marker RBPMS demonstrated that the large majority (

245 Here, we report on the embryonic stem cell marker, reduced expression 1 (REX1; also known as z

246 t contests the observations that cancer stem cell markers reliably identify the subset of tumor cells

247 These T1D SC-beta cells express beta-cell markers, respond to glucose both in vitro and in vi

248 Moreover, flow cytometric analyses for B-cell markers revealed an MDM2-ALT1-associated decrease i

249 ls expressing the myeloid-derived suppressor cell marker S100A9 only in a TN breast cancer environmen

250 Adventitial progenitors express the stem cell markers, Sca1 and CD34 (adventitial sca1-positive p

251 aled significantly higher expression of stem cell markers, self-renewal properties, thyrosphere forma

252 ession of the epithelial progenitor and stem cell marker sex-determining region Y-related box 2 (sox2

253 aracteristics, such as p63(+) cells (a basal-cell marker) showing luminal-like morphology, or cells d

254 2 as well as the supporting cell and Schwann cell marker Sox10; however, they did not colocalize with

255 factors led to the expression of the Schwann cell markers SOX10, KROX20 (EGR2), p75NTR (NGFR), MBP an

256 d with the stem cell and cochlear-supporting-cell marker Sox2 as well as the supporting cell and Schw

257 murine cerebellar cortex, expresses the stem cell markers Sox2 and Nestin, and lacks markers of glial

258 nt decrease in mRNA expression of known stem cell markers SOX2, OCT4, and NANOG.

259 also express a number of common dental stem cell markers (Sox2, Bmi1, beta-catenin and PH3) similar

260 etween CDC42 and type II alveolar epithelial cells marker SP-A, indicating the potential importance o

261 The alpha-cell markers, Sst and Hhex, are upregulated in Snord116p

262 rising the well-known human pluripotent stem cell marker stage-specific embryonic antigen 3 (SSEA3) a

263 ular co-localization of the mesenchymal stem cell markers STRO1 and C5L2.

264 T-cell markers such as CD3-by examining active recruitment

265 ion, they expressed typical glioma stem-like cell markers, such as CD133, CD15, and CD90.

266 In contrast to other stem cell markers, such as CD38, EPCR expression is maintaine

267 similar transcriptional changes in CD8(+) T cell markers, suggesting interventions that exploit meta

268 contained abundant glucagon and other alpha-cell markers, suggesting that alpha-cells drive much of

269 mmunolabeled for an RGC marker, not amacrine cell markers, suggesting that they are dopaminergic ipRG

270 s expressed stem, endothelial, and pericytic cell markers, suggesting these cells represent an undiff

271 the expression of AR and the neuroendocrine cell markers Synaptophysin and Chromogranin A.

272 C3 expressed higher levels of the effector T cell markers than TC3, suggesting that PD-L1 expression

273 rget was CD44, a cell adhesion gene and stem cell marker that controls tumorigenesis.

274 d identify Lmx1a as a novel enterochromaffin cell marker that is also essential for the production of

275 ronan (HA) induces the up-regulation of stem cell markers that display the hallmark CSC properties.

276 We found no T-cell markers that distinguished vaccinees that acquired

277 ls stimulates a durable upregulation of stem cell markers that epigenetically reprogram these cells.

278 Owing to the absence of exclusive stem cell markers, the location, multiplicity, dynamics and f

279 o validated 22 Abs specific for mouse immune cell markers to distinguish B cells, T cells, NK cells,

280 R)-T cells targeting uPAR, a novel senescent-cell marker, to treat liver adenocarcinoma and liver fib

281 onal skin showed a strong upregulation of NK-cell markers together with a dysbalanced expression of i

282 Both populations express stem cell marker TRA-1-60 and TNFR2, but only tubular CD133(+

283 g by expressing CD133 mRNA and protein, stem cell marker TRA-1-60, and pH3(S10) within 3 hours of tre

284 Conversely, expression of innate immune cell markers was increased post-treatment and was associ

285 A expression of Treg/Th1/Th2/Th17-associated cell markers was measured ex vivo.

286 h pure DCIS, a similar loss in myoepithelial cell markers was observed.

287 Notably, stem cell markers were also misregulated.

288 h serum IL-2, IL-4, and IL-6 and endothelial cell markers were analyzed by ELISA.

289 Cell markers were analyzed by using immunohistochemistry

290 Viral infection and expression of lung cell markers were analyzed using flow cytometry.

291 solated steatotic primary hepatocytes, and T-cell markers were assessed in hepatic lymphocytes after

292 Putative stem cell markers were detected in cultures grown in DMEM and

293 Cell death, inflammation, and tuft cell markers were downregulated in fat-1 mice in respons

294 o BBB function, a microglia and three immune cell markers were measured by qPCR in the prefrontal cor

295 Expression of several B-cell markers were significantly different in ACPA(+) RA

296 , endothelial, venous, angiogenic, and mural cell markers were significantly upregulated in miniature

297 rformed bulk RNA sequencing and found that B cell markers were the most differentially expressed gene

298 ed expression of oncofetal proteins and stem-cell markers, while low-risk tumors had low lin-28 homol

299 ntification of an LITR subset as a cytotoxic cell marker will allow for more effective monitoring of

300 f cells coexpressing intrinsic factor (chief cell marker), YFP (lineage marker), and GSII lectin (spa